George A. Scangos - 10 Mar 2022 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
President and CEO, Director
Signature
/s/ Howard Horn, Attorney-in-Fact
Issuer symbol
VIR
Transactions as of
10 Mar 2022
Net transactions value
$0
Form type
4
Filing time
06 Apr 2022, 17:22:32 UTC
Previous filing
22 Feb 2022
Next filing
21 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +111,000 +98% $0.000000 223,989 10 Mar 2022 Direct F1
holding VIR Common Stock 3,598,559 10 Mar 2022 See footnote F2
holding VIR Common Stock 61,660 10 Mar 2022 See footnote F3
holding VIR Common Stock 877,135 10 Mar 2022 See footnote F4
holding VIR Common Stock 61,660 10 Mar 2022 See footnote F5
holding VIR Common Stock 877,135 10 Mar 2022 See footnote F6
holding VIR Common Stock 115,000 10 Mar 2022 See footnote F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +222,000 $0.000000 222,000 10 Mar 2022 Common Stock 222,000 $29.48 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2 The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011.
F3 The shares are held in the name of the Jennifer Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
F4 The shares are held in the name of the Jennifer Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
F5 The shares are held in the name of the Katherine Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
F6 The shares are held in the name of the Katherine Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
F7 The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.
F8 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter.